BLU2864

BLU2864 is an orally active, highly selective, ATP-competitive PRKACA inhibitor (IC50=0.3 nM) . BLU2864 shows anti-tumor activity. BLU2864 can be used in cancer and polycystic kidney disease research[1][2].

Product Specifications

CAS Number

[2810747-89-6]

UNSPSC

12352005

Target

PKA

Type

Reference compound

Related Pathways

Stem Cell/Wnt; TGF-beta/Smad

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Cancer; Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/blu2864.html

Purity

99.50

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

FC1=CC(C(F)F)=CC2=C1[C@H]([C@@H](O)C2)NC(C(C=C3)=CN=C3C4=C(C(C)=CN5)C5=NC=C4)=O

Molecular Formula

C24H19F3N4O2

Molecular Weight

452.43

References & Citations

[1]Xiaofang Wang, et al. Protein Kinase A Downregulation Delays the Development and Progression of Polycystic Kidney Disease. J Am Soc Nephrol. 2022 Jun;33 (6) :1087-1104.|[2]Stefanie S. Schalm, et al. Evaluation of PRKACA as a Therapeutic Target for Fibrolamellar Carcinoma. bioRxiv 2022.01.31.477690.